Efficacy of prostate extract in the treatment of patients with chronic prostatitis caused by intracellular pathogens
https://doi.org/10.21518/2079-701X-2019-12-160-165
Abstract
Different statistical studies showed that chronic prostatitis (CP) is the most common urological disease among men aged 20 to 40 years. The etiological nature of intracellular pathogens in the development of CP is currently finding more and more evidence. The prostate extract acting on various pathogenesis units is of particular interest, taking into account the variety of pathogenetic mechanisms of the development of CP. A study of the efficacy and safety of prostate extract (rectal suppositories) combined with josamycin was conducted. Findings. Patients with CP caused by intracellular pathogens received josamycin therapy. The prostate extract was included in the treatment (rectal suppositories) in Group I. Both groups showed a significant improvement in symptoms and quality of life on the NIH-CPSI scale, both in total and in individual domains, and the differences between the groups were statistically insignificant. The number of leukocytes in the prostate gland secret reduced more significantly in the active treatment group.
Thus, the use of prostate extract increased the clinical efficacy of treatment, which correlates with data from the previous studies.
About the Authors
K. V. Kumachev
State Budgetary Healthcare Institution City Outpatient Clinic No 69 of Moscow Health Department
Russian Federation
Russian Federation
Kumachyov Kirill Vasilyevich - Cand. of Sci. (Med.), Urologist, SBHI «City Outpatient Clinic No 69 of Moscow Health Department»; District Urologist of Eastern Administrative District of Moscow.
111558, Moscow, Federativny Prospect, 31; Tel.: +7 (903) 241-35-24L. A. Logvinov
Best Clinic LLC
Russian Federation
Russian Federation
Logvinov Leonid Alekseevich - Cand. of Sci. (Med.), Urologist, Head of Urology Department.
117218, Moscow, Novocheremushkinskaya St., 34, Bldg. 2; Tel.: +7 (903) 270-40-16
References
1. Practical urology. A guide for physicians. Under the editorship of P.V. Glybochko, Yu.G. Alyaev. M.: Medforum, 2012. 352 p. (In Russ).
2. Apolikhin O.I, Abdullin II, Sivkov A.V., Oshchepkov V.N., Egorov A.A. Chronic prostatitis. Plenum of the Board of the Russian Urological Society. Materials. Saratov, June 8-10, 2004 M., 2004: 5-12. (In Russ).
3. Kriger J.N., Nyberg LJr., Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA. 1999;51:578-84.
4. Trapeznikova M.F., Dutov V.V., Urenkov S.B. et al. The role of bacterial flora in chronic prostatitis. In the book: 3rd All-Russian Conference «Men’s Health» M., 2006: 78-79. (In Russ).
5. Mazo E.B., Popov S.V Chronic bacterial prostatitis. Vrachebnoe Soslovie. 2004;1-2:18. (In Russ).
6. Smith C.P. Male chronic pelvic pain: An update. Indian J Urol. 2016;32(1):34-9.
7. Lipsky B.A., Byren I., Christopher T., Hoey C.T. Treatment of Bacterial Prostatitis. Clin Infect Dis. 2010;50(12):1641-1652.
8. Kogan M.I., Ibishev Kh.S., Naboka Yu.L. Etiological structure and antibiotic sensitivity of microorganisms isolated in chronic bacterial prostatitis. Consilium medicum. 2010;7:5-7. (In Russ).
9. Bozhedomov VA Current treatment options for chronic prostatitis. Andrologia i Genitalnaya Khirurgia. 2016;17(3):10-22. (In Russ).
10. Rees J., Abrahams M., Doble A. et al. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116(4):509-25.
11. Mo X., Zhu C., Gan J., Wang C., Wei F., Gong W., Cai Q. Prevalence and correlates of Mycoplasma genitalium infection among prostatitis patients in Shanghai, China. Sex Health. 2016 Jul 4.
12. Meares E.M., Stamey T.A. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968;5:492-518.
13. Nickel J.C., Weidner W. Chronic prostatitis: current concepts and antimicrobial therapy. Infect Urol. 2000;13:S22-S28.
14. Kudryavtsev Yu.V., Logvinov L.A., Kudryavtseva L. V. Helper/suppressor ratio in chronic prostatitis. Collection of scientific papers «Interpretation of findings of laboratory methods for the diagnosis of urological diseases» M. , 2003:198-203. (In Russ).
15. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. May 12, 2016.
16. Bonkat G., Pickard R., Bartoletti R. et al. Guidelines on rological infections. European Association of Urology, 2018.
17. Vinarov A.Z., Stoilov S.V., Kozyrev S.V. et al. Doxycycline (Unidox Solutab®) and/or josamy-cin (Vilprafen®) therapy of patients with prostatitis in real clinical practice. The results of TAURUS observational program. Urologia. 2015;3:75-8, 80-3. (In Russ).
18. Gorbachev A.G., Burakova M.A., Al-Shukri S. Kh. Prostatilen: experience and prospects for clinical use. SPb.: Science, 1995. 56 p. (In Russ).
19. Tkachuk V.N., Gorbachev A.G., Havinson V.Kh. The use of pros-tatilen in the treatment of patients with chronic prostatitis. Urologia i Nefrologia. 1991;6:40-43. (In Russ).
20. Al-Shukri S.Kh., Petrishchev N.N., Gorbachev A.G. et al. The effect of prostatilen on hemostasis in chronic prostatitis (clinical and experimental studies). Urologia i Nefrologia. 1997;3:38-41. (In Russ).
21. Tkachuk V.N. Chronic prostatitis. Medicine for all. M., 2006. 112 p. (In Russ).
Review
For citations:
Kumachev KV, Logvinov LA. Efficacy of prostate extract in the treatment of patients with chronic prostatitis caused by intracellular pathogens. Meditsinskiy sovet = Medical Council. 2019;(12):160-165. (In Russ.) https://doi.org/10.21518/2079-701X-2019-12-160-165
Views:
3266
Email this article 